Elanco Animal Health Incorporated (ELAN) - Stock Analysis
Last updated: Jun 1, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Animal-health recovery with concrete catalysts: Q1 2026 revenue grew 15% YoY to $1.371B and management raised full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and year-end leverage. New products including Befrena and Advantage Collar plus the New World screwworm backdrop add timely sector support.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Leverage Load ⢠Margin Recovery ⢠Cash Pressure ELAN has solid near-term liquidity and a stronger latest quarter, but high leverage, a heavy interest burden, weak full-year profitability, and intangible-heavy equity keep financial risk elevated.
Price Behavior
Key Price Behavior Insights: ⢠Volatile rebound ⢠Range resistance ⢠Support holding Support Level: $21.30-$21.70 Resistance Level: $24.00-$24.10 Over the last month, ELAN is modestly higher but still volatile, with a strong rebound from a mid-month low putting it back near $24 resistance without a confirmed breakout.
Sentiment & News
Key News Insights: ⢠Guidance raise ⢠Product launches ⢠Stock volatility Elanco delivered a strong Q1 with revenue and earnings beats, raised full-year guidance, and highlighted innovation-led growth and debt reduction, though the stock remained volatile.
AI Summary
ELAN is no longer just a turnaround betâthe key question is whether its Q1 growth and raised guidance can translate into durable free cash flow and faster deleveraging, because a sustained move toward 3.0xâ3.2x leverage would support a rerating while any cash-flow miss could quickly cap upside.
Description
Elanco Animal Health Inc. develops, manufactures and markets pharmaceuticals, vaccines and nutritional health products for companion animals and food-producing species, including treatments for parasites, infectious disease and common chronic conditions. The company distributes through third-party distributors, veterinarians and farm producers across beef, dairy, pork, poultry and aquaculture markets; it was founded in 1954 and is headquartered in Greenfield, Indiana.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 5 | Jun 12 | ELAN | Elanco Animal Health Incorporated | Animal-health recovery with concrete catalysts: Q1 2026 revenue grew 15% YoY to $1.371B and management raised full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and year-end leverage. New products including Befrena and Advantage Collar plus the New World screwworm backdrop add timely sector support. | Active | +0.0% |